Vaxcyte, Inc. (PCVX) Form 8-K — Sep 3, 2026
Vaxcyte appointed Luis Jodar, Ph.D., formerly Pfizer's Chief Medical Officer for Vaccines and Infectious Diseases, as Chief Medical Officer, and David McAvoy, J.D., formerly Teva's Chief Legal Officer, as Chief Legal Officer, per an 8-K filed September 3, 2026. Mikhail Eydelman continues as Senior Vice President, General Counsel. The company also narrowed guidance for its VAX-31 adult Phase 3 OPUS-1 topline safety, tolerability and immunogenicity data, now expected by the end of October 2026 versus prior guidance of the fourth quarter of 2026.
Key figures
- Opus1 topline guidance
- by end of October 2026, narrowed from prior Q4 2026 guidance
- Opus2 opus3 data guidance
- first half of 2027
- Opus program adults dosed
- 6191
- Vax31 dosed adults approx
- 3500
- Mc Avoy prior legal org size
- 235
Price after filing
Close on the filing date to close N calendar days later (from $61.17). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.